# Development and Implementation of Vaccine Made in Third World

MK Bhan, New Delhi, India

### **Partners**

**Public Sector** 

USA Roger Glass, Harry Greenberg, Richard L Ward

India C Durga Rao, Nita Bhandari, Pratima Ray,

Ramesh Kumar, MK Bhan


#### Non Government Sector

Society for Applied Studies, New Delhi Clinical trials

PATH, USA Management and finance

BBIL, Hyderabad Manufacturing

### Rotaviral Diarrhoea Vaccine Development



#### **Academic Institutions**

AIIMS, New Delhi-CDC, Atlanta IISc., Bangalore-Stanford University

NGO SAS, New Delhi

Rotaviral Diarrhoea Vaccine Candidates [116E and I321]

US Federal Government NIH NIAID

Industry
BBIL, Hyderabad

**Global Organizations**PATH

### Studies with Natural Rotavirus Infection in Delhi and Bangalore

- Neonatal infections with rotavirus common.
- Natural neonatal infection with RV associated with significant and prolonged viral shedding in Delhi and Bangalore.
- ≥4 fold rise in RV specific serum and salivary IgA in over half the neonatally infected infants.
- Neonatal infection protects (46%) against subsequent rotavirus diarrhea over 2 year period in Delhi.
- Evidence of protection also recently shown from Bangalore.
   following neonatal infection.

# Nosocomial neonatal infection with 116E at AIIMS is immunogenic

- Specific IgA response
  - serum 56%
  - saliva 68%
- Neutralizing antibody response
  - serum 37%
  - saliva 56%

JID 1988, Clin Diag Lab Immunol 1998

# Characteristics of the AIIMS neonatal strain 116E

- Bovine-human rotavirus reassortant:
   P8 [11] G9
- VP6, NSP1, NSP4:
- Human rotavirus origin

J Clin Microbiol 1994, Virus Genes 1997

 Neonatal strain I321 from Bangalore is characterized as G10P11

Strain contains 2 segments of human rotavirus origin and
 9 segments of bovine origin including those encoding
 VP4 and VP7

# Lack of maternal antibody may predispose to 116E neonatal infection

	Cord blood neutralizing antibody to 116E >200		
Infected with 116E	7/18 (39%)		
Infected with other rotaviruses	10/12 (83%)		
Non-infected	15/20 (75%)		

Clin Diag Lab Immunol 1998

## Rotavirus Serotypes: India 1996-8

### P types

53% common P

24% P6: 11% with common G

9% with G9

4% with mixed or NT

### **G** types

64% common G

17% G9: 9% with P6

5% with P8

3% with mixed or NT

Multicenter study: AIIMS-CDC collaboration

# Experimental live virus vaccine pool lot 116E-I and I321 prepared by Dyna Corp PRI with NIH assistance

	116E	I321
PAGMK	2	2
Ma104	7	8
SPAGMK	10	8
Vaccine potency	2.0 x 10 <sup>6</sup> FFu/ml	2.2 x 10 <sup>6</sup> FFu/ml


Safety Studies in Adults and Children in Cincinnati

Adult, children and infant studies in India using Dyna Corp vaccine

# Infant Safety Study of Candidate Vaccines 116E and I321 in Delhi

### Key features

- Randomized controlled three cell trial
- Single dose 10<sup>5</sup> FFu
- Subjects: 90 healthy, non malnourished infants aged 8 weeks
- Period: January to May 2005
- Site: Low to middle income urban
- Placebo: Crystal of potassium permanganate added to sodium bicarbonate buffer



## Participants Experiencing Mild (Grade 1) or Moderate (Grade 2) or Severe (Grade 3) Adverse Events in First 14 Days Possibly or Remotely Related to Administration of the Vaccines or Placebo

Illness episodes	Placebo (n=30)	I321 (n=29)*	116E (n=30)
History of fever	5	1	6
Measured temperature >99.5°F (>37.5° C)	1	-	2
Irritable infant	3	-	1
Diarrhea without vomiting	3	8	5
Diarrhea with vomiting	2	-	-
Diarrhea and stool positive for vaccine virus	-	-	2 <sup>†</sup>
Abdominal distension	1	-	-
Inconsolable crying	2	1	-
Vomiting only	-	-	2
Skin rash		1	1

<sup>\*</sup>One infant refused participation on day 2 post vaccination; †G9[P11]

Note: 1 infant each in the placebo and I321 groups had 2 episodes of fever, another infant in the I321 group had 2 episodes of diarrhea. Two infants in the 116E group had two episodes of diarrhea each

## Stool Positivity for Rotavirus Antigen by ELISA Pre-immunization and Days 3, 7 and 28 Post Administration of Vaccines or Placebo

	Placebo	I321	116E
	(n=30)	(n=30)	(n=30)
Day 0	-	-	1
	(n=30)	(n=30)	(n=30)
Day 3	1	1	10
	(n=30)	(n=29)	(n=30)
Day 7	1	1	7
	(n=30)	(n=29)	(n=30)
Day 3 or 7	2	1	12
	(n=30)	(n=28)	(n=30)
Day 3 or 7 or 28	2 (G12[P6]: 1, NS:1)	2 (G9[P8]:1, NS:1)	12 (G9[P11]:11, G9[P6]:1)

Figures in parenthesis indicate shedding of vaccine virus as per G and P types. NS: sample not sufficient

# Enrolled Infants with ≥4 Fold Rise in Rota Specific Serum IgA Between Baseline and Day 28 Post Administration of Vaccines or Placebo

	Placebo (n=30)	l321 (n=28) <sup>a</sup>	116E (n=30)	
Number (%)	6 (20.0)	11 (39.3)	22 (73.3) <sup>b</sup>	
95% CI	7.7% to 38.5%	21.5% to 59.4%	54.1% to 87.7%	

In the 116E group, 11/30 infants shed the vaccine virus in stools and seroconverted, 1/30 shed a wild rotavirus strain and seroconverted and 10/30 only seroconverted

<sup>&</sup>lt;sup>a</sup>Two day 28 samples were not available

bChi-square for trend, p < 0.0001

Immunogenecity of live oral human rota virus vaccine in previously uninfected infants from US and India (randomized double-blind placebo-controlled trials)

Country	Age of infants vaccinated (weeks)	RN vaccine candidate	Dose of vaccine (P.f.u.)	Antirotavirus IgA Antibody (units / ml) response (n%)		Neutralizing Antibodies
				after dose1	after dose2	
USA (Bernstein et al, 1999)	10-16	attenuated 89-12	10 <sup>5</sup>	98/107 (91.6)		74/107 (69.2)
USA (Bernstein et al, 1998)	6-26	attenuated 89-12	105	16/20 (80)	19/20 (95)	7/20 (35)
India	6-26	116E	105			

### 116E VERO CELL CANDIDATE VACCINE

- Experimental live virus vero cell vaccine pool lot 116E prepared by M/s Bharat Biotech Intrl.Ltd. (BBIL) under supervision of the international rotavirus vaccine development group.
- Liquid, active biological ingredient of RV 116E strains bulk, stabilizer, antibiotics, and buffer solution.
- Vaccine stored at -70°C ± 5°C at BBIL

"A Double-Blind Randomized Placebo Controlled Dose Escalating Phase Ib/Ila Study to Evaluate the Safety and Immunogenicity of Live Attenuated Rotavirus Vaccine 116E in Healthy Non Malnourished Infants 8-20 Weeks of Age"

#### **Objectives**:

#### **Primary**

To evaluate the safety of Vero cell based 116E rotavirus vaccine candidate strains administered three times orally at 4-week intervals at three dosage levels [104, 105 and 106 fluorescence focus units (FFu)] in healthy non-malnourished infants 8 to 20 weeks of age.


#### Secondary

To evaluate the immunogenicity of Vero cell based 116E rotavirus vaccine candidate strains administered three times orally at 4-week intervals at three dosage levels (104, 105 and 106 FFu) in healthy non-malnourished infants 8 to 20 weeks of age.

#### FLOW CHART OF THE STUDY STRATEGY FOR EACH OF THE THREE DOSAGES 104, 105 AND 106



#### **Clinical development, Overview**



Vero, BBIL

- Potential gains of the global partnership
  - Capacity building and training
  - Pooling of expertise
- Monitoring and problem solving
  - Availability of critical biological reagents/material
  - Clinical development planning
  - Financial resources
  - High quality programme management.

### Challenges

- Shifting from a science investigation model to product development programme required changing roles of partners
- Vaccine for Global use versus for National use.

### **CHALLENGES**

#### **BBIL**

- Quality human resource
- Leadership
- Clinical development expertise
- QA/QC
- Formulation and stability
- Mindset Global versus National
- Pre-clinical testing
- Financial resources
- Emerging Competition

### CHALLENGES FOR CLINICAL TRIALS

- SAS is a not for profit structure;
   Stability, retaining human resource, building capacity, Financial support in between trials.
   Role of private CRO's
- Availability of laboratory over the years that can perform validated assays in large numbers in time.

### ROLE OF REGULATORY AUTHORITIES

- DBT and ICMR arranged discussion on aprior approval of clinical development plan.
- DBT and ICMR generated decision making rules for Drug Controller General of India.
- DBT and ICMR created a policy for introduction of new vaccine in India.

# FEW UNANSWERED QUESTIONS: CHALLENGES REGARDING THE NEXT GENERATION OF ROTAVIRUS VACCINES

- Will live oral rotavirus vaccines work well for children in the developing world?
- How safe will they be; intussusception issues.
- Will parents accept a vaccine for only 1 cause of childhood diarrhea?

#